Dawn Maroney became president of Medicare Advantage insurer Alignment Healthcare at a fraught moment.
Not only is the health insurance industry reeling from the murder of UnitedHealthcare CEO Brian Thompson in December and the backlash against the sector that followed, but the Medicare Advantage market is in a sustained period of struggle as insurers clamor to soothe investors and boost profit margins.
Related: Right place, wrong time: BCBS insurers report Medicare gains
In January, Alignment Healthcare promoted Maroney from president of markets and CEO of Alignment Health Plan to president of the parent company under founder and CEO John Kao. Alignment is one of the fastest-growing Medicare Advantage carriers: Membership rose 58% to 189,100 at the beginning of the year, far exceeding the 4% average across the sector.
The interview has been edited for length and clarity.
What are Alignment’s priorities for 2025?
The Medicare Part D prescription drug benefit is a big area of focus. It's getting more refined. How do you track that to make sure that people are getting access to drugs that are at zero copays, underneath that $35 insulin allotment and not going over the $2,000 maximum out-of-pocket? How do you make sure that there's a care plan around what they're getting access to?
There is a lot of work that goes on behind the scenes from an operational standpoint. If somebody says, "I can't afford a particular drug," and they're eligible for the new payment plan this year, how do you make sure you educate on it?
What do you think of the Medicare Advantage advance notice
Overall, it seems pretty reasonable. I want to understand more about the marketing pieces of it. I do not believe that agencies themselves should be marketing specific benefits, other than highlighting that, "I'm an agency, and I represent Medicare Advantage, and I can be an option for you."
We've got to still clean up that, so I like CMS’ position on that.